期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌分子靶向治疗研究进展 被引量：11

暂未订购
导出
摘要 乳腺癌是女性常见恶性肿瘤,因其发病率、病死率较高,严重危害女性健康.近年来,从基因水平对恶性肿瘤发病机制的研究不断深入,分子靶向治疗逐渐广泛应用于临床.分子靶向治疗是以肿瘤细胞内特异表达的某些标志性分子为靶点,有效干预该分子参与的影响肿瘤发生、发展的细胞信号转导通路,从而抑制肿瘤生长和转移的一种治疗方法.因其特异性强,不良反应轻微,治疗效果显著,是目前肿瘤治疗中最有前景的治疗方法.本文针对近年来乳腺癌分子靶向治疗研究进展做一综述.
作者 崔玉洁 张凯 苏同义 朱铁年
机构地区 解放军白求恩国际和平医院肿瘤科 河北医科大学研究生学院
出处 《解放军医药杂志》 CAS 2014年第1期95-98,共4页 Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金 国家自然科学基金(81071846) 河北省自然科学基金(H2013505059) 河北省科技厅国际合作项目(12396107D) 吴阶平基金(320.6750.12604)
关键词 乳腺肿瘤 分子靶向 治疗
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献37

  • 1曾巧,周巧丹,陈琳,寇沛,廖盼丽,许楚瓯,付会玲,刘萍,刘丽丽,徐钢.Erbin基因沉默对乳腺癌细胞生物学行为的影响[J].中华肿瘤防治杂志,2013,20(17):1291-1294. 被引量：1
  • 2刘琪,左文述,王新昭,穆殿斌,李同义,刘岩松,于志勇.乳腺癌原发灶和淋巴结转移灶激素受体及HER-2与Ki-67表达相关性分析[J].中华肿瘤防治杂志,2013,20(15):1153-1157. 被引量：24
  • 3Kaur A,Dasanu C A. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma[J].{H}EXPERT OPINION ON PHARMACOTHERAPY,2011,(16):2493-2503.
  • 4Mukohara T. Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer[J].Chemother Res Pract,2011.730360.
  • 5Saxena R,Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer:current status and future clinical perspective[J].{H}Medicinal Research Reviews,2012,(01):166-215.
  • 6Mukai H. Treatment strategy for HER2-positive breast cancer[J].{H}International Journal of Clinical Oncology,2010,(04):335-340.
  • 7Slamon D J,Leyland Jones B,Shak S. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2[J].{H}New England Journal of Medicine,2001,(11):783-792.
  • 8Extra J M,Cognetti F,Chan S. 672 Randomised phase Ⅱ trial (M77001) of trastuzumab (Herceptin(R[J].{H}EUROPEAN JOURNAL OF CANCER,2003,(05):S202.
  • 9Von Minckwitz G,Zielinski C,Maarteense E. Capecitabine vs.capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment:The TBP phase Ⅲ study (GBG 26/BIG 3-05)[J].{H}Journal of Clinical Oncology,2008,(15):1025.
  • 10Kaufman B,Mackey J R,Clemens M R. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phase Ⅲ TAnDEM study[J].{H}Journal of Clinical Oncology,2009,(33):5529-5537.

二级参考文献13

  • 1Marsh KL, Varley JM. Frequent alteration of cell cycle regula-tion early-stage breast lesions as detected by immunohistochem-istry[J]. Br J Cancer, 1998?77(9) : 1460-1468.
  • 2Goldhirsch A, Wood WC? Coates AS? et al. Strategies for sub-types-dealing with the diversity of breast cancer j highlights ofthe St. Gallen International Expert Consensus on the PrimaryTherapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011,22(8):1736-1747.
  • 3Harris L,Fritsche H,Mennel R,et al. American Society of Clini-cal Oncology 2007 update of recommendations for the use oftumor markers in breast cancer[J]. J Clin Oncol,2007,25(33):5287-5312.
  • 4Sara E,Monaco MD, Yue Wu.et al. Assessment of estrogen re-ceptor (ER) , progesterone receptor (PR), and human epidermalgrowth factor receptor 2 (HER2) status in the fine needle aspi-rates of metastatic breast carcinomas[J], Diagnostic Cytopathol-ogy,2013,41(4):308-315.
  • 5Lower EE,Glass E,Blau R,et al. HER-2/neu expression in pri-mary and metastatic breast cancer[J]. Breast Cancer Res Treat,2009,113(2):301-306.
  • 6Yerushalmi R, Wood R,Ravdin PM,et al. Ki-67 in breast canc-er: prognostic and predictive potentiaI[J]. Lancet Oncol,2010,11(2):174-183.
  • 7Tawfik K,Kimler BF,Davis MK,et al. Ki-67 expression in axil-lary lymph node metastases in breat cancer is prognostically sig-nificant[J]. Hum Pathol?2013,44(1) :39-46.
  • 8David Padua Joan Massague.Roles of TGFβ in metastasis[J].Cell Research,2009,19(1):89-102. 被引量：58
  • 9赵海波,程雪雁,刘金君,聂学诚,李强.乳腺癌原发灶与腋淋巴结转移灶ER和PR及c-erbB-2表达的对照研究[J].中华肿瘤防治杂志,2011,18(8):594-596. 被引量：17
  • 10邓智平,朱江,马宁强,宋张骏,汪存涛,王雁,李逢生,韩丕华,王虎霞.乳腺癌ER、PR、HER-2在原发灶及复发转移灶中表达变化[J].现代肿瘤医学,2011,19(8):1562-1564. 被引量：8

共引文献23

同被引文献113

  • 1钱军,华海清,秦叔逵.通关藤制剂抗肿瘤作用研究进展[J].中国中药杂志,2009,34(1):11-13. 被引量：29
  • 2章俊.siRNA干扰GADD45联合顺铂对人卵巢癌细胞增殖及凋亡的影响[J].中国老年学杂志,2014,34(6):1595-1597. 被引量：1
  • 3王芳.临床护理路径在乳腺癌患者健康教育中的应用[J].现代预防医学,2007,34(1):113-113. 被引量：20
  • 4Siegel R L, Miller K D, Jemal A. Cancer statistics, 2016[J1. CA Cancer J Clin, 2016,66(1) :7-30.
  • 5Tan D S, Marchi6 C, Jones R L, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients [ J ]. Breast Cancer Res Treat, 2008,111 ( 1 ) :27-44.
  • 6Bidard F C, Matthieu M C, Chollet P, et al. P53 status and efficacy of primary anthracyclines/alkylating agent- based regimen according to breast cancer molecular clas- ses[J]. Ann Oncol, 2008,19(7) :1261-1265.
  • 7Hurvitz S, Mead M. Triple-negative breast cancer: ad- vancements in characterization and treatment approach [J]. Curr Opin Obstet Gyneeol, 2016,28( 1 ) :59-69.
  • 8Sasa M, Bando Y, Takahashi M, et al. Screening for basal marker expression is necessary for decision of ther- apeutic strategy for triple-negative breast cancer [J]. J Surg Oncol, 2008,97( 1 ) :30-34.
  • 9Wang X, Chao L, Ma G, et al. Increased expression of osteopontin in patients with triple-negative breast cancer[J]. Enr J Clin Invest, 2008,38(6) :438-446.
  • 10Keenan T, Moy B, Mroz E A, et al. Comparison of the genomie landscape between primary breast cancer in afri- can American versus white women and the association of racial differences with tumor recurrence [ J ]. J Clin On- col, 2015,33(31 ) :3621-3627.

引证文献11

二级引证文献67

解放军医药杂志
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部